Switch TZP

Active not recruiting

Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide

Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry

Lead sponsor

LMC Diabetes & Endocrinology Ltd.

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

650

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥30•HbA1c ≥7.5%

Primary endpoint

•Body Weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07889453

Org study IDSwitch SEMA TZP

Timeline

Milestones

Study start2026-10-15actual

Study first posted2026-10-22actual

Last update posted2026-10-22actual

Primary completion2026-12estimated (month precision)

Study completion2027-06estimated (month precision)

Assets

Investigational agents

Semaglutide Tirzepatide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

The study populations will include adults living with T2D and adults living with obesity without diabetes, who switched from injectable semaglutide to tirzepatide, or adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide.

Inclusion criteria

for T2D Cohort:

•Age 18 years old or older

•A clinical diagnosis of T2D ≥ 1 year

•Baseline HbA1c ≥ 7.5%

•≥ one HbA1c value up to 6 months (+ 90 days) prior to index date

•≥ one body weight value up to 6 months (+ 90 days) prior to index date

•Initiated injectable semaglutide or switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025

•Use of injectable semaglutide for ≥ 3 months for both the control and switch cohort

•If using real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM), CGM use for ≥ 3 months

•Seen by an LMC endocrinologist in the last 18 months as of the query date

•Informed data consent for their medical record data to be used for research purposes

Inclusion Criteria for Obesity (non-diabetes) Cohort:

•Age 18 years old or older

•BMI ≥ 30 kg/m2

•Baseline HbA1c < 6.5%

•≥ one HbA1c value up to 6 months (+ 90 days) prior to index date

•≥ one body weight value up to 6 months (+ 90 days) prior to index date

•Initiated injectable semaglutide and switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025

•Use of injectable semaglutide for ≥ 3 months

•Seen by an LMC endocrinologist in the last 18 months as of the query date

•Informed data consent for their medical record data to be used for research purposes

Exclusion criteria

•Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults

•Prior use of tirzepatide

•Were pregnant at the time of semaglutide initiation or semaglutide-to-tirzepatide switch or became pregnant during follow-up period

•Bariatric surgery

Endpoints (31)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Renal / kidney

Cardiometabolic biomarkers

Other (unclassified)

MASH / liver

Safety / tolerability / PK

Weight & body composition

8 endpoints

Primary/protocol endpoint

Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Primary/protocol endpoint

Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Percent Body Weight at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in Percent Body Weight at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in BMI at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in Waist Circumference at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Glycemic / diabetes

8 endpoints

Secondary/protocol endpoint

Change from Baseline in HbA1c at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Insulin use (none, basal only, basal-bolus) - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

descriptive

Secondary/protocol endpoint

Change from Baseline in Percent time in range (TIR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Percent Time Above Range (TAR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Percent Time Below Range (TBR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Mean glucose at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Glycemic Variability at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in HbA1c at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

MASH / liver

2 endpoints

Secondary/protocol endpoint

Change from Baseline in Alanine Transaminase (ALT) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in ALT at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Renal / kidney

4 endpoints

Secondary/protocol endpoint

Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Urine Albumin-to-Creatinine Ratio (uACR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in eGFR at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in uACR at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints

Secondary/protocol endpoint

Change from Baseline in Blood Pressure at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Lipids at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in Blood Pressure at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Other/protocol endpoint

Change from Baseline in Lipids at 12 Months - Obesity Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Percent TBR in Level 2 Hypoglycemia at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, event

Other (unclassified)

4 endpoints

Secondary/protocol endpoint/low confidence

Number of Antihyperglycemic Agents (AHAs) at 12 Months - T2D Cohort

Time frame:Follow-up (6-12 months)

event count, event

Secondary/protocol endpoint/low confidence

Proportion of Individuals who Discontinued Treatment during Follow-up Period (6-12 Months) - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in Percent Time In Tight Range (TITR) at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Percent sensor capture at 12 Months - T2D Cohort

Time frame:Baseline to follow-up (6-12 months)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.